Magnetic Resonance Imaging Guided Tumor Dose Boost In Prostate Brachytherapy
Y. Hu,G. Jia,D.D. Martin,Y. Takayama,Z.K. Shah,E.Y. Kim,N.A. Mayr,M.V. Knopp,J.Z. Wang
DOI: https://doi.org/10.1016/j.ijrobp.2008.06.477
2008-01-01
Abstract:In current practice of prostate brachytherapy, radioactive seeds are implanted under the guidance of ultrasound or CT imaging. Due to lack of tumor information, the entire prostate becomes the treatment target, which limits the dose to tumor because of the tolerance of nearby critical structures. Recently, a novel method using 3T MRI to identify tumor burden within prostate has been developed and validated with pathology. In this study, we used the MRI information to guide our treatment planning to boost tumor region while maintaining low dose to the critical structures, and performed a dosimetric evaluation of the MRI-guided plans vs. the conventional plans. The study was conducted on 11 patients (mean age 63, range 48-79, years), who had histologic diagnosis of prostate cancer between January 2007 and June 2007. All patients were imaged on a 3T MRI using a phased-array surface coil. Besides T1W and T2W images, three functional sequences, including diffusion-weighted, T2-mapping, and dynamic contrast-enhanced MRI, were used for tumor identification. Axial T2 images with resolution of 0.4×0.4×3.3 mm3 were loaded for treatment planning with Variseed, Varian Inc. Two plans with Pd-103 seeds were completed for each patient: one based on MRI images with information on tumor location; and the other based on traditional CT images that have only anatomical information. The dosimetric target goals and constraints were adopted from our routine procedure. Dose-Volume Histograms for MRI-based gross tumor volume (GTV), prostate, and other structures were recorded. The dosimetric parameters, including D90, V100, Dmax, and equivalent uniform dose (EUD), were used to evaluate and compare the two plans. The average target size for the 11 patients was 33.2 cm3 (range, 20.0-48.2 cm3) for prostate, and 2.3 cm3 (range, 0.2-4.0 cm3) for GTV. Most of the GTVs were located in the peripheral zone. Six patients had only one tumor focus, 4 patients had two, and 1 patient had three. The dosimetric parameters of the two plans were similar for prostate (D90: 141±2 Gy vs.141±3 Gy), rectum (Dmax: 112±19 Gy vs. 116±22 Gy), and urethra (V100: 78±14% vs. 78±14%) doses. However the MRI-guided plans enhanced a much higher boost dose to the GTV than the conventional plans (D90: 230±19 Gy vs. 149±13 Gy, p < 0.0001). The EUD to the GTV was 109±12 Gy vs. 98±7 Gy (p = 0.002) for the two techniques. This indicates an average increase of tumor EUD increase by 10% (range, 6%-34%) using the MRI guidance, which may result in an improvement of TCP for currently 70% to approximately 85% for intermediate-risk patients. Our study demonstrates that the quality of prostate implant can be improved by MRI-based tumor targeting. Image-guided dose boost to the GTV is feasible while maintaining low dose levels to the adjacent critical structures.